Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival in a pandemic
Jee, J.; Zhang, J.; Lavery, J.; Waters, M.; Fong, C.; Minn, A.; Glickman, M.; Panageas, K.; Sawyers, C.; Schultz, N.
Show abstract
Real-world data suggest that SARS-CoV-2 mRNA vaccines, administered within 100 days of immune checkpoint inhibitor (ICI) treatment ("peri-ICI vaccination"), may improve ICI effectiveness, potentially through synergistic immune priming. Although peri-ICI vaccination was associated with longer survival when we applied a previous framework to our independent dataset, additional patterns emerged. Peri-ICI vaccination benefit diminished after 2021, a pattern confirmed in re-analysis of a published cohort. Benefit extended to patients treated with non-ICI antineoplastics. Benefit also dissipated in landmarked analyses restricted to periods of vaccine eligibility. Finally, progression-free survival in time periods with high vaccine uptake was not longer than in periods without vaccination. These analyses suggest peri-ICI vaccinations observed association with survival largely reflects selection bias in which patients with better prognosis were more likely to receive SARS-CoV-2 vaccines.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer 93%
- AI-Driven Predictive Biomarker Discovery with Contrastive Learning to Improve Clinical Trial Outcomes 92%
- Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer 91%
Similar papers in this journal
- Efficacy of PD-(L)1 blockade monotherapy compared to PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: A cohort study 94%
- Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+ T cells in the tumor microenvironment and predicts clinical outcome in early- and late-phase clinical trials 94%
- Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy 94%
Similar papers in this journal
- Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent but clinically inapparent in cancer patients under immune checkpoint therapy 94%
- Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence 93%
- Additivity predicts the efficacy of most approved combination therapies for advanced cancer 93%
Similar papers in this journal
- Tumor-specific activity of precision medicines in the NCI-MATCH trial 93%
- Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up 93%
- Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer 92%
Similar papers in this journal
- Predicting the Tumor Microenvironment Composition and Immunotherapy Response in Non-Small Cell Lung Cancer from Digital Histopathology Images 94%
- Fraction of copy-number alterations significantly predicts survival following immunotherapy in a few cancers 92%
- Explainable, federated deep learning model predicts disease progression risk of cutaneous squamous cell carcinoma 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.